Short answer
Travere Therapeutics, Inc. (TVTX) filed an 8-K current report with the SEC on June 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Chief Research Officer William Rote retiring February 17, 2027, after 10 years with Travere.
Travere Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Research Officer William Rote retiring February 17, 2027, after 10 years with Travere
- Jula Inrig assumes research leadership July 1, 2026, becoming Executive Vice President, Head of R&D and Chief Medical Officer
- Planned succession reduces near-term continuity risk through Rote’s transition support and expected consulting arrangement
- Research leadership transition remains subject to business needs and other execution risks disclosed by the company
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Travere Therapeutics, Inc. 8-K filings
Get the next TVTX 8-K as it lands
Follow TVTX for push alerts, or ask the research agent what this filing means.